☰

Laith Q. Al-Mawsawi, Ph.D. - Publications

Affiliations: 
2007 Pharmaceutical Sciences University of Southern California, Los Angeles, CA, United States 
Area:
Pharmacology, Biochemistry
Tree Info Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Al-Mawsawi LQ, Wu NC, Olson CA, Shi VC, Qi H, Zheng X, Wu TT, Sun R. High-throughput profiling of point mutations across the HIV-1 genome. Retrovirology. 11: 124. PMID 25522661 DOI: 10.1186/s12977-014-0124-6  0.391
2014 Al-Mawsawi LQ, Wu NC, De La Cruz J, Shi VC, Wu TT, Daar ES, Lewis MJ, Yang OO, Sun R. Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing. Aids Research and Human Retroviruses. 30: 806-11. PMID 24914638 DOI: 10.1089/Aid.2014.0097  0.341
2014 Qi H, Olson CA, Wu NC, Ke R, Loverdo C, Chu V, Truong S, Remenyi R, Chen Z, Du Y, Su SY, Al-Mawsawi LQ, Wu TT, Chen SH, Lin CY, et al. A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. Plos Pathogens. 10: e1004064. PMID 24722365 DOI: 10.1371/Journal.Ppat.1004064  0.327
2012 Serrao E, Thys W, Demeulemeester J, Al-Mawsawi LQ, Christ F, Debyser Z, Neamati N. A symmetric region of the HIV-1 integrase dimerization interface is essential for viral replication. Plos One. 7: e45177. PMID 23028829 DOI: 10.1371/Journal.Pone.0045177  0.752
2011 Al-Mawsawi LQ, Neamati N. Allosteric inhibitor development targeting HIV-1 integrase. Chemmedchem. 6: 228-41. PMID 21275045 DOI: 10.1002/Cmdc.201000443  0.74
2011 Al-Mawsawi LQ, Neamati N. New Paradigm for Integrase Inhibition: Blocking Enzyme Function without Directly Targeting the Active Site Hiv-1 Integrase: Mechanism and Inhibitor Design. 457-476. DOI: 10.1002/9781118015377.ch29  0.494
2010 Debnath B, Al-Mawsawi LQ, Neamati N. Are we living in the end of the blockbuster drug era? Drug News & Perspectives. 23: 670-84. PMID 21180653 DOI: 10.1358/Dnp.2010.23.10.1506088  0.515
2008 Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opinion On Emerging Drugs. 13: 213-25. PMID 18537517 DOI: 10.1517/14728214.13.2.213  0.694
2008 Al-Mawsawi LQ, Hombrouck A, Dayam R, Debyser Z, Neamati N. Four-tiered π interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity Virology. 377: 355-363. PMID 18514248 DOI: 10.1016/J.Virol.2008.04.030  0.633
2008 Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N. Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: Insight into integrase-DNA complex formation and catalysis Febs Letters. 582: 1425-1430. PMID 18331842 DOI: 10.1016/J.Febslet.2008.02.076  0.511
2008 Dayam R, Al-Mawsawi LQ, Zawahir Z, Witvrouw M, Debyser Z, Neamati N. Quinolone 3-carboxylic acid pharmacophore: Design of second generation HIV-1 integrase inhibitors Journal of Medicinal Chemistry. 51: 1136-1144. PMID 18281931 DOI: 10.1021/Jm070609B  0.677
2008 Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: 2005-2006 update. Medicinal Research Reviews. 28: 118-54. PMID 17979144 DOI: 10.1002/Med.20116  0.738
2007 Al-Mawsawi LQ, Dayam R, Taheri L, Witvrouw M, Debyser Z, Neamati N. Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors Bioorganic and Medicinal Chemistry Letters. 17: 6472-6475. PMID 17950601 DOI: 10.1016/J.Bmcl.2007.09.102  0.701
2007 Dayam R, Al-Mawsawi LQ, Neamati N. Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. Bioorganic & Medicinal Chemistry Letters. 17: 6155-9. PMID 17911021 DOI: 10.1016/J.Bmcl.2007.09.061  0.682
2007 Al-Mawsawi LQ, Neamati N. Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. Trends in Pharmacological Sciences. 28: 526-35. PMID 17888520 DOI: 10.1016/J.Tips.2007.09.005  0.67
2007 Deng J, Sanchez T, Al-Mawsawi LQ, Dayam R, Yunes RA, Garofalo A, Bolger MB, Neamati N. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore. Bioorganic & Medicinal Chemistry. 15: 4985-5002. PMID 17502148 DOI: 10.1016/J.Bmc.2007.04.041  0.717
2007 Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs in R&D. 8: 155-68. PMID 17472411 DOI: 10.2165/00126839-200708030-00003  0.696
2007 Al-Mawsawi LQ, Sechi M, Neamati N. Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivity. Febs Letters. 581: 1151-6. PMID 17328897 DOI: 10.1016/J.Febslet.2007.02.023  0.672
2007 Deng J, Dayam R, Al-Mawsawi LQ, Neamati N. Design of second generation HIV-1 integrase inhibitors. Current Pharmaceutical Design. 13: 129-41. PMID 17269923 DOI: 10.2174/138161207779313687  0.694
2007 Dayam R, Grande F, Al-Mawsawi LQ, Neamati N. Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu Expert Opinion On Therapeutic Patents. 17: 83-102. DOI: 10.1517/13543776.17.1.83  0.568
2006 Sechi M, Bacchi A, Carcelli M, Compari C, Duce E, Fisicaro E, Rogolino D, Gates P, Derudas M, Al-Mawsawi LQ, Neamati N. From ligand to complexes: inhibition of human immunodeficiency virus type 1 integrase by beta-diketo acid metal complexes. Journal of Medicinal Chemistry. 49: 4248-60. PMID 16821784 DOI: 10.1021/Jm060193M  0.583
2006 Al-Mawsawi LQ, Fikkert V, Dayam R, Witvrouw M, Burke TR, Borchers CH, Neamati N. Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proceedings of the National Academy of Sciences of the United States of America. 103: 10080-5. PMID 16785440 DOI: 10.1073/Pnas.0511254103  0.628
Show low-probability matches.